JP7687637B2 - 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法 - Google Patents

抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法 Download PDF

Info

Publication number
JP7687637B2
JP7687637B2 JP2023533162A JP2023533162A JP7687637B2 JP 7687637 B2 JP7687637 B2 JP 7687637B2 JP 2023533162 A JP2023533162 A JP 2023533162A JP 2023533162 A JP2023533162 A JP 2023533162A JP 7687637 B2 JP7687637 B2 JP 7687637B2
Authority
JP
Japan
Prior art keywords
residue
amino acid
cov
sars
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023533162A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023282281A1 (https=
JPWO2023282281A5 (https=
Inventor
好則 藤吉
駿 中村
莉紗 野村
幸宏 谷村
亜希子 亀川
修孝 沼本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cespia
Original Assignee
Cespia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cespia filed Critical Cespia
Publication of JPWO2023282281A1 publication Critical patent/JPWO2023282281A1/ja
Publication of JPWO2023282281A5 publication Critical patent/JPWO2023282281A5/ja
Application granted granted Critical
Publication of JP7687637B2 publication Critical patent/JP7687637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023533162A 2021-07-07 2022-07-06 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法 Active JP7687637B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2021113006 2021-07-07
JP2021113006 2021-07-07
JP2021145370 2021-09-07
JP2021145370 2021-09-07
JP2022103949 2022-06-28
JP2022103949 2022-06-28
PCT/JP2022/026804 WO2023282281A1 (ja) 2021-07-07 2022-07-06 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法

Publications (3)

Publication Number Publication Date
JPWO2023282281A1 JPWO2023282281A1 (https=) 2023-01-12
JPWO2023282281A5 JPWO2023282281A5 (https=) 2024-03-18
JP7687637B2 true JP7687637B2 (ja) 2025-06-03

Family

ID=84801690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533162A Active JP7687637B2 (ja) 2021-07-07 2022-07-06 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法

Country Status (5)

Country Link
US (1) US20240309059A1 (https=)
EP (1) EP4368631A4 (https=)
JP (1) JP7687637B2 (https=)
TW (1) TW202317599A (https=)
WO (1) WO2023282281A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026068449A1 (en) * 2024-09-24 2026-04-02 Universite De Geneve Antibody- like binding molecules and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106559844B (zh) 2015-09-25 2020-03-24 电信科学技术研究院 一种上行传输资源调度及上行传输方法、装置
JP6974512B2 (ja) 2020-01-21 2021-12-01 本田技研工業株式会社 車両のフロア構造
KR20230017215A (ko) * 2020-05-27 2023-02-03 유니버시티 오브 워싱턴 드 노보 설계한 단백질 스위치에 기반한 모듈형의 일반화 가능한 바이오센서 플랫폼
EP4182027A1 (en) * 2020-07-14 2023-05-24 University of Washington Sars-cov-2 inhibitors
JP2022103949A (ja) 2020-12-28 2022-07-08 セイコーエプソン株式会社 インクセット及び記録方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIBILASHVILI, R., et al.，Biomed Khim，2021年，Vol. 67, Issue 3，pp. 244-250
CAMPOS, L., et al.，J Phys Chem B，2021年，Vol. 125, Issue 24，pp. 6572-6586
CAO, L., et al.，SCIENCE，2020年，Vol. 370, Issue 6515，pp. 426-431
CHOWDHURY, S., et al.，J Phys Chem，2020年，Vol. 124, Issue 44，pp. 9785-9792
HAN, Y., et al.，ACS Nano，2020年，Vol. 14，pp. 5143-5147
SITTHIYOTHA, T., et al.，J Phys Chem B，2020年，Vol. 124, Issue 48，pp. 10930-10942

Also Published As

Publication number Publication date
EP4368631A4 (en) 2025-08-13
WO2023282281A1 (ja) 2023-01-12
EP4368631A1 (en) 2024-05-15
US20240309059A1 (en) 2024-09-19
JPWO2023282281A1 (https=) 2023-01-12
TW202317599A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
WO2023214576A1 (ja) Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
US9914753B2 (en) Peptide compounds to regulate the complement system
JP6041843B2 (ja) ＩＬ−１ｒａの凝集を低下させる方法
TW202208404A (zh) 新穎錨蛋白重複結合蛋白質及其用途
US20120028880A1 (en) Vegfr-1/nrp-1 targeting peptides
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
EA017957B1 (ru) Композиции и способы, ингибирующие грипп
TW201629085A (zh) 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途
JP2007525204A (ja) トランスフォーミング増殖因子β１（ＴＧＦ−β１）との結合能を有するペプチド
WO2023019723A1 (zh) 单克隆抗体32c7及其制备方法和用途
WO2023019724A1 (zh) 单克隆抗体35b5及其制备方法和用途
JP2023542453A (ja) Ｓａｒｓ－ｃｏｖ－２阻害剤
JP7687637B2 (ja) 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法
JP5806112B2 (ja) デング出血熱およびデングショック症候群を含む免疫介在性デング熱感染症およびデング熱感染症の抗体依存性増強を処置するための方法
CN111601815A (zh) 靶向细胞中c-Myc的嵌合分子
US20100331524A1 (en) Immunomodulatory protein and useful embodiments thereof
US10428128B2 (en) Helix-grafted proteins as inhibitors of disease-relevant protein-protein interactions
CN118159550B (zh) 经修饰的多肽及其在镇痛领域的应用
CA3153354A1 (en) Computational design of alpha(v) beta (6) integrin binding proteins
US9809627B2 (en) Cyclized transthyretin peptide and methods of use therefor
WO2018175518A1 (en) Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
US20130225508A1 (en) Peptide capable of binding to immunoglobulin
JP2017160168A (ja) インフルエンザ治療剤
WO2025176787A1 (en) Ccl5 variants for modulating gpr75

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20241011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7687637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150